A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20mg), Multi-National, Multicentre Study of Weight-Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities.
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2009
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms RIO-ASIA
- Sponsors Sanofi
- 07 Jul 2008 Actual number of patients are 643 as reported by ClinicalTrials.gov.
- 07 Jul 2008 Actual completion date for this trial Apr 2007 is added as reported by ClinicalTrials.gov.
- 02 Aug 2007 Status changed from in progress to completed.